Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature.

Aged CD4-Positive T-Lymphocytes / metabolism CD8-Positive T-Lymphocytes / metabolism Cholangitis / chemically induced Eosinophils / metabolism Humans Liver / pathology Male Nivolumab / adverse effects Prednisolone / administration & dosage Stomach Neoplasms / drug therapy
drug-induced liver injury eosinophils immune-related adverse event nivolumab-related cholangitis prednisolone

Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Jun 2019
Historique:
pubmed: 26 2 2019
medline: 26 9 2019
entrez: 26 2 2019
Statut: ppublish

Résumé

The patient was a 76-year-old man who was treated with nivolumab due to recurrent gastric cancer. A blood examination revealed grade 3 alkaline phosphatase (ALP) elevation. A histopathological examination revealed marked portal infiltration, including eosinophils and CD4+ and CD8+ T lymphocytes, suggesting nivolumab-related cholangitis accompanied by the features of both an immune-related adverse event (irAE) and drug-induced liver injury (DILI) with allergic reaction. The patient's ALP level immediately decreased after the administration of prednisolone. Although nivolumab-related cholangitis, a rare irAE, has been reported to be refractory to steroid therapy, patients with features of irAE and allergic DILI might immediately respond to prednisolone.

Identifiants

DOI: 10.2169/internalmedicine.2330-18 PMID: 30799364 PMC: PMC6630117
pubmed: 30799364
doi: 10.2169/internalmedicine.2330-18
pmc: PMC6630117
doi:

Substances chimiques

Nivolumab 31YO63LBSN
Prednisolone 9PHQ9Y1OLM

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1747-1752

Références

Hepatol Res. 2003 Nov;27(3):192-195
pubmed: 14585395
Intern Med. 2009;48(13):1143-7
pubmed: 19571447
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
HPB Surg. 2010;2010:906496
pubmed: 21076681
J Clin Oncol. 2011 Mar 20;29(9):e237-40
pubmed: 21220617
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Hepatology. 2014 Feb;59(2):661-70
pubmed: 24037963
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Lancet Oncol. 2016 Jul;17(7):994-1003
pubmed: 27283863
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
JAMA Oncol. 2016 Dec 1;2(12):1607-1616
pubmed: 27540850
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Ann Oncol. 2017 Mar 1;28(3):671-672
pubmed: 27993797
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Invest New Drugs. 2017 Aug;35(4):529-536
pubmed: 28317087
J Immunother Cancer. 2017 May 16;5:40
pubmed: 28515940
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1498-1506
pubmed: 28882625
Cancer Immunol Immunother. 2018 Jan;67(1):61-65
pubmed: 28913619
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
ESMO Open. 2017 Oct 10;2(4):e000268
pubmed: 29081991
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Endoscopy. 2018 Sep;50(9):E259-E261
pubmed: 29969801

Auteurs

Koji Sawada (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Tatsuya Shonaka (T)

Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan.

Yuji Nishikawa (Y)

Division of Tumor Pathology, Department of Pathology, Asahikawa Medical University, Japan.

Kimiharu Hasegawa (K)

Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan.

Hidemi Hayashi (H)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Takumu Hasebe (T)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Shunsuke Nakajima (S)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Katsuya Ikuta (K)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Mikihiro Fujiya (M)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Hiroyuki Furukawa (H)

Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan.

Toshikatsu Okumura (T)

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladie des voies biliaires › Maladies des canaux biliaires › Angiocholite › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Granulocytes › Granulocytes éosinophiles › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Système digestif › Foie › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Nivolumab › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènetriols › Prednisolone › Successful Treatment of Nivolumab-related...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › Successful Treatment of Nivolumab-related...